Sign Up Today and Learn More About DocPlanner Stock
Invest in or calculate the value of your shares in DocPlanner or other pre-IPO companies through EquityZen's platform.
DocPlanner Stock (DOCL)
Online appointment management for Doctors
About DocPlanner Stock
Founded
2011
Total Funding
34.0M
Industries
Software, Artificial Intelligence, Data and Analytics
DocPlanner enables patients to find great, local physicians online and book an appointment. Every month, we help over 7 million patients find an appropriate medical specialist in their neighborhood. On DocPlanner, patients have access to a rapidly growing database of over 1.4 million specialists, and can then schedule an appointment using the doctor's calendar. Choosing the right physician is made easier by real reviews and opinions posted on the website by the patients themselves. We publish all content-related comments in order to help patients decide on the right physician.
DocPlanner Press Mentions
Stay in the know about the latest news on DocPlanner
Leading global healthcare platform Docplanner acquires company MyDr sp. z o. o. - a leader in the Polish practice management software (PMS) sector.
prnewswire • Feb 23, 2023
Polish healthtech DocPlanner acquires Brazilian software developer Feegow
ain • Aug 13, 2022
Warsaw-based digital healthcare unicorn Docplanner acquires Munich-based Jameda
eu-startups • Nov 25, 2021
Healthcare booking and management platform and Docplanner snaps up Hubert Burda Media property Jameda
tech • Nov 25, 2021
DocPlanner enters Germany by acquiring Jameda
sifted • Nov 23, 2021
DocPlanner Management
Leadership team at DocPlanner
Co-Founder
Lucjan Samulowski
CFO / Board Member
Peter Bialo
Join now and verify your accreditation status to gain access to:
- DocPlanner current valuation
- DocPlanner stock price
- Available deals in DocPlanner and all other companies
- Deal offering documents
- EquityZen's proprietary data and insights, including
- Cap tables, which include funding history by Share Class and Liquidity Preferences
- Company Highlights
- Business Model
- Risk Factors
How to invest in DocPlanner stock?
Accredited investors can buy pre-IPO stock in companies like DocPlanner through EquityZen funds. These investments are made available by existing DocPlanner shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell DocPlanner stock?
Shareholders can sell their DocPlanner stock through EquityZen's private company marketplace. EquityZen's network includes over 330K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 43K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
